Out-licensing: PITDC: Novel Compound For Treatment Of Treatment Of Bacterial Infections And/or Renal Cancer Disease

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Out-licensing
View

PITDC: Novel compound for treatment of treatment of bacterial infections and/or renal cancer disease

Active ingredient for the treatment of bacterial infections and/or renal cancer diseases

Full description

The present invention discloses a novel 6-fluoro-1,4-dihydro-7- [4-(2-hydroxyiminoethyl)-1-piperazinyl] -4-oxoquinoline-3- carboxylic acid derivatives(formula I), with a process for their preparation, and with pharmaceutical compositions containing them as the active ingredient for the treatment of bacterial infections and/or renal cancer diseases.

Development status

Preclinical

Type of business relationship sought

Licensees sought.

Licensing contact

Ms. CK Liu
Licensing Manager
PITDC

Contact directly

Company details

BiotechEast Co., Ltd. (Technology Partner)

BiotechEast is a one-stop, full-service marketing consultancy for those looking to take advantage of the dynamic opportunities in Taiwan's burgeoning life science industry.

View profile

Visit website

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Modified Sugar Substrates and Methods of Use

Aerosolized Vaccines

Use of Saccharides Cross-Reactive with Bacillus anthracis Spore Glycoprotein as a Vaccine Against Anthrax

Neo-Penotran® topical broad spectrum anti-infective vaginal pessary and cream for the treatment of three main types of vaginal infections and mixed forms of vaginitis.

Related categories

Industry sector: Biotechnology; Drug discovery
Therapeutic target: Infectious diseases / Diseases / Infection, bacterial(other); Infectious diseases; Oncology; Oncology / Kidney cancer / Renal cell carcinoma

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us